Deadline
Passed
Lead Plaintiff Deadline: August 02, 2021
Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
16
Nov 2020
22
Mar 2021
the Company’s Phase 2a trial results failed to live up to the Company’s expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322’s potential. These statements materially misled the market and artificially inflated the value of Frequency’s common stock.
In order to be included in the lawsuit, you must have incurred a loss on shares of Frequency Therapeutics purchased during the class period listed above.
If you suffered a loss in Frequency Therapeutics during the relevant time frame, you have until August 02, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.